MedTrace Logo

Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells

NCT04484402 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-07-30

No results posted yet for this study

Summary

Treatment of patients with inflammatory-dystrophic diseases of the cornea using autologous limbal stem cells (corneal epithelial stem cells) or adipose-derived mesenchymal stem cells

Conditions

  • Corneal Ulcer
  • Corneal Disease
  • Corneal Dystrophy

Interventions

BIOLOGICAL

mesenchymal stem cells

Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution

BIOLOGICAL

limbal stem cells

Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution

OTHER

standard treatment

Standard treatment according to the Clinical protocols

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Igor Volotovski, Prof · Head of the Lab of Institute of Biophysics and Cell Engineering

  • Liudmila Marchenko, Prof · Head of the Department of eyes diseases of Belarusian State Medical University

  • Zinaida Kvacheva · Leading researcher, Institute of Biophysics and Cell Engineering

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-03
Primary Completion
2019-12-30
Completion
2019-12-30

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04484402 on ClinicalTrials.gov